AU2013240191B2 - Methods for treating neoplasia - Google Patents

Methods for treating neoplasia Download PDF

Info

Publication number
AU2013240191B2
AU2013240191B2 AU2013240191A AU2013240191A AU2013240191B2 AU 2013240191 B2 AU2013240191 B2 AU 2013240191B2 AU 2013240191 A AU2013240191 A AU 2013240191A AU 2013240191 A AU2013240191 A AU 2013240191A AU 2013240191 B2 AU2013240191 B2 AU 2013240191B2
Authority
AU
Australia
Prior art keywords
alt
cancer
cells
pct
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013240191A
Other languages
English (en)
Other versions
AU2013240191A1 (en
Inventor
Peter Rhode
Jinghai Wen
Hing C. Wong
Wenxin Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altor Bioscience LLC
Original Assignee
Altor Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience LLC filed Critical Altor Bioscience LLC
Publication of AU2013240191A1 publication Critical patent/AU2013240191A1/en
Application granted granted Critical
Publication of AU2013240191B2 publication Critical patent/AU2013240191B2/en
Priority to AU2018203584A priority Critical patent/AU2018203584A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2013240191A 2012-03-29 2013-03-15 Methods for treating neoplasia Active AU2013240191B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018203584A AU2018203584A1 (en) 2012-03-29 2018-05-22 Methods for treating neoplasia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261617370P 2012-03-29 2012-03-29
US61/617,370 2012-03-29
PCT/US2013/032269 WO2013148337A1 (en) 2012-03-29 2013-03-15 Methods for treating neoplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203584A Division AU2018203584A1 (en) 2012-03-29 2018-05-22 Methods for treating neoplasia

Publications (2)

Publication Number Publication Date
AU2013240191A1 AU2013240191A1 (en) 2014-10-09
AU2013240191B2 true AU2013240191B2 (en) 2018-02-22

Family

ID=49261086

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013240191A Active AU2013240191B2 (en) 2012-03-29 2013-03-15 Methods for treating neoplasia
AU2018203584A Abandoned AU2018203584A1 (en) 2012-03-29 2018-05-22 Methods for treating neoplasia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018203584A Abandoned AU2018203584A1 (en) 2012-03-29 2018-05-22 Methods for treating neoplasia

Country Status (8)

Country Link
US (2) US20150216937A1 (https=)
EP (1) EP2830648A4 (https=)
JP (2) JP6639228B2 (https=)
KR (2) KR20190134832A (https=)
CN (2) CN104470535A (https=)
AU (2) AU2013240191B2 (https=)
CA (1) CA2868431A1 (https=)
WO (1) WO2013148337A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4124339T (lt) 2014-03-06 2025-11-10 Vaisto įvedimo sistemos ir būdai šlapimo pūslės vėžiui gydyti gemcitabinu
EP3875152B1 (en) 2014-12-15 2024-04-10 Washington University Compositions and methods for targeted cytokine delivery
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
CA3011374A1 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
CN118453872A (zh) * 2016-05-06 2024-08-09 塔里斯生物医药公司 治疗下尿路尿道上皮癌的方法
ES3014658T3 (en) * 2016-10-05 2025-04-23 Univ Central Florida Res Found Inc Methods and compositions related to nk cell and anti-pdl1 cancer therapies
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US11046768B2 (en) * 2017-01-27 2021-06-29 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
BR112020000832A2 (pt) 2017-07-25 2020-07-21 Taris Biomedical Llc métodos para tratar metástase tumoral
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
CN108392634A (zh) * 2018-03-28 2018-08-14 清华大学 B7s1抑制剂在制备肝癌药物中的用途
US12325734B2 (en) 2019-01-15 2025-06-10 Altor Bioscience Llc Human immunodeficiency virus-specific T cell receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062603A2 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Methods of treating lung diseases
WO2008042436A2 (en) * 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
US7851599B2 (en) * 2006-04-07 2010-12-14 Philogen S.P.A. Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537973B1 (en) * 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
MXPA05012723A (es) * 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
WO2009117117A1 (en) * 2008-03-19 2009-09-24 Altor Bioscience Corporation T cell receptor fusions and conjugates and methods of use there of
WO2011066379A2 (en) * 2009-11-24 2011-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. METHOD OF REDUCING INTRATUMORAL pHe AND ACID-MEDIATED INVASION

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062603A2 (en) * 2003-01-09 2004-07-29 Arizeke Pharmaceuticals Inc. Methods of treating lung diseases
US7851599B2 (en) * 2006-04-07 2010-12-14 Philogen S.P.A. Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabine
WO2008042436A2 (en) * 2006-10-03 2008-04-10 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISHMAN ET AL., CLINICAL CANCER RESEARCH, (2011), vol. 17, no. 24, pp 7765 - 7775 *
National Institutes of Health, Clinical Trials.gov, "How to read a study record", website https://clinicaltrials.gov/ct2/help/how-read-study , accessed 6/28/2016. *
YAFI ET AL., "First-and second-line therapy for metastatic urothelial carcinoma of the bladder", CURRENT ONCOLOGY, (2011), vol. 18, no. 1, pages E25 - E34 *

Also Published As

Publication number Publication date
CN104470535A (zh) 2015-03-25
US20190328838A1 (en) 2019-10-31
KR20150002706A (ko) 2015-01-07
AU2013240191A1 (en) 2014-10-09
AU2018203584A1 (en) 2018-06-14
CN111420032A (zh) 2020-07-17
JP2015512914A (ja) 2015-04-30
WO2013148337A1 (en) 2013-10-03
JP2018172414A (ja) 2018-11-08
US20150216937A1 (en) 2015-08-06
EP2830648A1 (en) 2015-02-04
JP6639228B2 (ja) 2020-02-05
EP2830648A4 (en) 2015-12-02
KR20190134832A (ko) 2019-12-04
CA2868431A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
AU2013240191B2 (en) Methods for treating neoplasia
Zhang et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
US20250000938A1 (en) Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy
JP7157839B2 (ja) 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP7223055B2 (ja) 癌治療のための併用免疫療法及びサイトカイン制御療法
AU2019379325B2 (en) Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
CA2999294A1 (en) Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
CN119816313A (zh) 含有抗人表皮生长因子受体2（her2）嵌合抗原受体（car）的自然杀伤细胞的给药方法
Rasoulouniriana et al. A distinct subset of FcγRI-expressing Th1 cells exert antibody-mediated cytotoxic activity
US20230338423A1 (en) Targetable immune checkpoint for immunotherapy
Trigo Synergistic Antitumor Effect of Combined Laser Thermotherapy and Immunomodulators in Malignant Melanoma: Pilot Studies
US20210338656A1 (en) Immunostimulatory agents in combination with angiogenesis inhibitors
HK40119904A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
Singh Role of focused ultrasound in CD40 mediated anti-tumor immunity
Gomez Isolation and characterization of human glioma cell models resistant to alloreactive cytotoxic T lymphocytes
Baird et al. Society for Immunotherapy of Cancer 2018 Annual Meeting Posters

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)